EPB152	Country of birth influences INSTI prescription in treatment-naive patients living with HIV in France	E-poster	ART in acute, first- and second-line therapies
EPB153	Starting antiretroviral therapy (ART) at the first HIV-specialist appointment with or without baseline laboratory data with BIC/FTC/TAF (The BIFAST study)	E-poster	ART in acute, first- and second-line therapies
OAB0302	Efficacy and safety of dolutegravir plusemtricitabinevs combined antiretroviral therapy for the maintenance of viral suppression: 144-week results of the SIMPL'HIV trial	Oral abstract session with live Q&A	ART in acute, first- and second-line therapies
OAB0303	Dual therapy based on DRVr plus 3TC in HIV-1 naïve patients: global 48 week results from ANDES Study	Oral abstract session with live Q&A	ART in acute, first- and second-line therapies
OAB0304	Dolutegravir versus efavirenz-400 as first-line ART in Cameroon: week 192 data of NAMSAL trial	Oral abstract session with live Q&A	ART in acute, first- and second-line therapies
OAB0305	Survival in advanced AIDS patients treated with efavirenz or dolutegravir in Brazil: a multicenter, observational study	Oral abstract session with live Q&A	ART in acute, first- and second-line therapies
PESUB19	Rapid ART initiation: a four-years observational study	Poster exhibition	ART in acute, first- and second-line therapies
EPE118	Enhanced adherence counselling (EAC) enrollment via phone: a strategy to improve timeliness of enrollment and completion of EAC among HIV-infected patients with high viral load at Nkwen Baptist Hospital, Cameroon	E-poster	Approaches to viral load monitoring at scale
EPE119	Applying a seven-step approach to rapidly improve viral load testing coverage: lessons from Burundi, Nigeria and Togo	E-poster	Approaches to viral load monitoring at scale
EPE120	HIV drug resistance testing gap in Malawi's HIV programme advocates for increased local genotyping capacity	E-poster	Approaches to viral load monitoring at scale